Related to this topic: Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Hanta Virus Infection

The preferred names are Haemorrhagic fever with renal syndrome (HFRS) or Hantavirus cardiopulmonary syndrome (HCPS). It is also known as Korean haemorrhagic fever, Epidemic Haemorrhagic syndrome, Nephropathia epidemica.

Historical
  • Identifying the aetiological agent took from the Korean War (1951-53) to 1976. 3,000 soldiers had developed a disease characterised by fever and renal failure, with a fatality rate of 10%.
  • In 1993 the unknown Hantavirus (named Muerto Canyon virus - later changed to Sin Nombre - that is Spanish for "no name") and the rodent reservoir (deer mouse Paromyscus maniculatus) were identified. This was 6 months after an outbreak of unexplained pulmonary illness in "The Four Corners area" of the USA i.e. Arizona, New Mexico, Colorado, and Utah.
  • Retrospective serological investigations on unexplained pulmonary deaths, put the earliest proven case in 1959, though it is recognised in Navajo Indian medical traditions (associated with mice).
Pathogenesis

Hanta virus is named after the Hantaan River in Korea. It is a bunyavirus usually classified with the viral haemorrhagic fevers.

  • Over a dozen variations of Hanta virus have been discovered from all over the world, each associated with a specific rodent reservoir.
  • They cause 2 distinct clinical pictures:
    • Haemorrhagic fever with renal syndrome (HFRS) is usually seen in Asia and Europe.
    • Hantavirus cardiopulmonary syndrome (HCPS) was first recognised in New Mexico in 1993 and that is the form that is found in America.
  • Hanta viruses infect endothelial cells and in haemorrhagic fever with renal syndrome (HFRS) the cells of the kidney are infected.
  • In Hantavirus cardiopulmonary syndrome (HCPS) the pulmonary microvasculature and the cells of the spleen and lymph nodes are infected causing a massive, pulmonary-specific immune response. The damage to pulmonary endothelium increases capillary permeability and leads to fulminant pulmonary oedema.
Risk factors
  • Human infection usually occurs from inhalation of virus in aerosol from the urine, faeces, or saliva of infected rodents.
  • Other means include direct transmission via the fingers to mucus membranes, eating contaminated food, or bites (rare).
  • The Andes variation can be spread by human to human contact.
  • Dry sweeping or vacuum cleaning areas or infected rodent droppings is a high risk as particles are put into the air.
  • Construction, utility, pest control workers entering dirty vacant buildings are at particular risk.
Epidemiology
  • The virus tends to strike healthy young adults with a slight preponderance for men, because of occupational factors.
  • The Andes variation often affects children, who seem to suffer a milder disease than adults, unless they are under 1 year.
  • China has about 100,00 cases a year.
  • It does occur at times in Northern Europe. Worldwide there are thought to be over 200,000 cases a year, most in Eastern Europe, central and east Asia. In America most cases are in Argentina and Chile, but it is not uncommon in southern states of the USA, and is also found in Canada.

The table below gives numbers of cases and deaths reported in America between 1993 and 2004.1 The total also includes figures from Panama, Paraguay and Uruguay.

COUNTRY Argentina Bolivia Brazil Canada Chile USA Total
CASES 591 36 321 88 331 362 1910
DEATHS 11 17 71   124 132 384
Presentation

Hantavirus cardiopulmonary syndrome

  • Incubation period of 2 or 3 weeks.
  • There is a prodromal phase of fever, chills and myalgia that lasts 3 to 10 days, followed by rapid deterioration over 24 hours.
  • There is cardio-pulmonary failure with pulmonary oedema.
  • Those who recover may do so as rapidly as they became unwell. There is a marked diuresis.
  • Early diagnosis is difficult as symptoms are not much different from many other viral infections.

The haemorrhagic fever with renal syndrome

  • Also has an incubation period of 2 or 3 weeks with relatively nonspecific symptoms.
  • The febrile phase is 3 to 7 days, associated with head, abdominal and back pain, with eventual heavy proteinuria.
  • In the severest cases there is a period of several hours to 2 days, with first appearance of haemorrhages associated with lethal shock syndrome.
  • The oliguric phase lasts 3 to 7 days with associated nausea, vomiting, and acute renal failure, often combined with hypertension due to simultaneous hypervolaemia.
  • The diuretic phase lasts days to weeks. There may be further problems with electrolytes and secondary infection.
  • Convalescence lasts 2 or 3 months, usually with full recovery of renal function.
Investigations

Hantavirus cardiopulmonary syndrome

  • In the early stages there may be a normal FBC or slight thrombocytopenia. WCC does not rise until later in the disease. An elevated haematocrit means haemoconcentration and is an ominous sign.
  • A falling platelet count is highly indicative of the cardiopulmonary phase beginning.
  • AST and LDH are often raised.
  • There are 3 available serological tests for the virus:
    • Enzyme-linked immunosorbent assay detects circulating IgM and IgG antibodies.
    • Western blot assay indicates acute infection.
    • There is also a rapid immunoblot strip assay (RIBA) with 100% sensitivity during the illness.
  • CXR may show evidence of pulmonary oedema from the outset, but it usually develops over the next few days. Kerley B lines are common. Pleural effusion is seen in the late phase. The heart size in normal.
  • ECG helps rule out myocardial infarction. Sinus tachycardia is common. Death usually occurs with pulseless electrical activity (electro-mechanical dissociation).

The haemorrhagic fever with renal syndrome

This variety shows abnormalities of the renal rather than pulmonary system.

  • Albuminuria can be heavy.
  • The rise in creatinine will depend upon the severity of the disease.
  • There are also various methods of detecting antibody. Direct immunofluoresence is often used but quality control is essential and not always good.2
Management
  • Largely supportive.
  • The antiviral ribavarin is of no value3 although antibiotics may be required for secondary infection. A third-generation cephalosporin and an aminoglycoside are good first-line treatment.4 Consider adding a fluoroquinolone for Legionella species and chloramphenicol if pneumonic plague is in the differential diagnosis.
  • Management of fluids and electrolytes may be required. Inotropic support may be required to maintain MAP >70mmHg.
  • In HCPR intubation and respiratory support may be required. If the hospital has adult extracorporeal membrane oxygenation (ECMO) facilities, consider this early on. ECMO supports the failing heart and lungs long enough to allow recovery.
Prognosis

The renal haemorrhagic variety has a mortality rate around 10%.
The more virulent HCPS had a the mortality rate of approximately 80% in the intial outbreak. Now, because of increased recognition of the disease and more aggressive intervention e.g. ECMO or early mechanical ventilation, the rate is approximately 38%.4 Most deaths occur within 24 hours of hospital admission.
Those who recover tend to do so completely so that several weeks after being in pulmonary oedema a young person may have no significant impairment of exercise tolerance.

Prevention

Hantavirus is a zoonosis. Contact with infected rodents or their excreta is the means of spread.

  • The virus is fragile and can easily be killed by fat solvents (alcohol), household detergents, disinfectants, and bleach. Thus thorough wetting before cleaning (using gloves) is effective.
  • Based on current human population growth and development trends, hantavirus diseases will become more common in the near future unless public health measures are taken to curtail or eliminate rodents from human communities.5
  • A vaccine is being developed but its efficacy is not entirely satisfactory, and it is not ready for commercial exploitation.6,7
  • Passive immunity with immunoglobulin may possibly be of value.8


Document References
  1. Pan American Health Organisation. Number of Cases and Deaths from Hantavirus Pulmonary Syndrome (HPS)
  2. Biel SS, Donoso Mantke O, Lemmer K, et al; Quality control measures for the serological diagnosis of hantavirus infections. J Clin Virol. 2003 Dec;28(3):248-56. [abstract]
  3. Mertz GJ, Miedzinski L, Goade D, et al; Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis. 2004 Nov 1;39(9):1307-13. Epub 2004 Oct 11. [abstract]
  4. Lumumba-Kasongo M, Gang M. Hantavirus Cardiopulmonary Syndrome. e-Medicine; April 2006
  5. Lednicky JA; Hantaviruses. a short review. Arch Pathol Lab Med. 2003 Jan;127(1):30-5. [abstract]
  6. Cho HW, Howard CR; Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax). Vaccine. 1999 Jun 4;17(20-21):2569-75. [abstract]
  7. Maes P, Clement J, Gavrilovskaya I, et al; Hantaviruses: immunology, treatment, and prevention. Viral Immunol. 2004;17(4):481-97. [abstract]
  8. Ferres M, Vial P; Hantavirus infection in children. Curr Opin Pediatr. 2004 Feb;16(1):70-5. [abstract]

Internet and Further Reading Acknowledgements EMIS is grateful to Dr Hayley Willacy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 2232
Document Version: 20
DocRef: bgp1998
Last Updated: 12 Apr 2007
Review Date: 11 Apr 2009














Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site






Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page